Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-P01 as Consolidation Therapy in Stage III CRC or NSCLC
NCT07504484Phase 1Completed
- Sponsor
- Ying Yuan Chemical Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-P01 in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), sponsored by Ying Yuan Chemical Pharmaceutical. Primary endpoints: Treatment-Related Adverse Events at 7 months and 1-Year Recurrence-Free Survival Rate. Started Oct 2020; status: completed.
02
Drugs
iNeo-Vac-P01
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07504484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504484.